Abivax is trading at $94.30, down 4.1%, as investors digest its September 21 first-half results.
- Net loss widened to €165.9 million, and EPS of $(2.43) missed the $(1.08) consensus estimate; Wedbush and Truist subsequently reduced their price targets.
- Cash runway through late 2029 and a late-Q4 obefazimod NDA timeline provide offsets, while near-term spending and leadership changes weigh on sentiment.